Hangzhou Tigermed Consulting Co., Ltd
300347
Rank in Stocks
#3217
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
Share Price
$7.44
Market Cap
$5.49B
Change (1 day)
-2.99%
Change (1 year)
-0.42%
Country
CN
Trade Hangzhou Tigermed Consulting Co., Ltd (300347)
Category
Healthcare
P/E ratio for Hangzhou Tigermed Consulting Co., Ltd (300347)
P/E ratio as of October 2026 TTM: 620.75
According to Hangzhou Tigermed Consulting Co., Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 620.75. At the end of 2024 the company had a P/E ratio of 116.35.
P/E ratio history for Hangzhou Tigermed Consulting Co., Ltd from 2009 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 620.75 | 1,038.57% |
| 2025 | 54.52 | -53.14% |
| 2024 | 116.35 | 413.51% |
| 2023 | 22.66 | -49.84% |
| 2022 | 45.17 | 16.64% |
| 2021 | 38.73 | -47.52% |
| 2020 | 73.79 | 32.05% |
| 2019 | 55.89 | 34.74% |
| 2018 | 41.48 | -28.95% |
| 2017 | 58.37 | -35.18% |
| 2016 | 90.05 | 5.48% |
| 2015 | 85.38 | 63.88% |
| 2014 | 52.10 | -27.90% |
| 2013 | 72.26 | 92.73% |
| 2012 | 37.49 | -10.84% |
| 2011 | 42.05 | -32.77% |
| 2010 | 62.55 | -71.25% |
| 2009 | 217.57 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 30.83 | -95.03% |
US
|
|
| -29.16 | -104.70% |
US
|
|
| -25.99 | -104.19% |
AU
|
|
| 22.43 | -96.39% |
BE
|
|
| 31.22 | -94.97% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.